ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™, is thrilled to announce that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine’s Laboratory for Cell and Gene Medicine (LCGM), has been honored with the first-ever G-Rex® Grant. This prestigious $300,000 award will facilitate the rapid development of Stanford Medicine’s G-Rex platform for CAR-T cell therapy manufacturing, which will be available to both internal researchers and external developers seeking its advanced development and manufacturing capabilities.
“Stanford’s LCGM anticipates an increasing demand for clinical trials, and the G-Rex Grant will be instrumental in addressing that need,” stated Dr. Feldman.
John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, expressed, “We are proud to present the inaugural G-Rex Grant to Dr. Feldman and his team at Stanford Medicine LCGM. Stanford University is renowned for its cutting-edge research and groundbreaking achievements. Their work aligns seamlessly with Wilson Wolf’s mission to provide hope to cancer patients, one G-Rex at a time.”
The G-Rex Grant will support Stanford Medicine LCGM’s upcoming Phase 1 trial targeting GPC2+ pediatric neuroblastoma and medulloblastoma. In response to FDA recommendations for earlier development and implementation of potency assays, Stanford Medicine LCGM plans to utilize Bio-Techne’s advanced automated multiplexing immunoassay platform, Ella™, for potency assays during final drug product release.
Additionally, Stanford Medicine LCGM will collaborate with CellReady, the world’s first and only G-Rex-based contract development and manufacturing organization (CDMO), to benefit from their expertise in creating G-Rex master batch records that ensure manufacturing simplicity, efficiency, and repeatability.
Stanford Medicine LCGM also aims to advance a novel technology developed by Wilson Wolf, which allows for closed-system T cell purification directly within a G-Rex device, eliminating the need for costly ancillary equipment.
ScaleReady’s G-Rex Grant Program is a $20 million initiative designed to propel the advancement of cell and gene-modified cell therapy (CGT) development and manufacturing. The program awards individual grants of up to $300,000 and provides recipients with exclusive access to ScaleReady’s consortium of G-Rex Grant Partners, offering best-in-class tools, technologies, and unparalleled expertise in cGMP manufacturing, quality and regulatory affairs, and CGT business operations.
